Scleroderma Diagnostics and Therapeutics Market - Global Industry Analysis
Scleroderma Diagnostics and Therapeutics Market by Drug Class (Immunosuppressive Agents, Corticosteroids, Endothelin Receptor Agonists, Calcium Channel Blockers, Chelating Agents, PDE-5 Inhibitors, H2 Blockers, Prostacyclin Analogues, ACE Inhibitors, and Proton Pump Inhibitors), by Indication (Systemic and Localized), and by Diagnostic Test Type (Imaging Techniques, Skin Biopsy, Electrocardiogram and Echocardiogram, Pulmonary Function Tests, and Blood Test): Global Industry Perspective, Comprehensive Analysis and Forecast, 2017 - 2024
Published Date: 10-Sep-2018Healthcare
Category: Report Format : PDF
Report Code: ZMR-3321
Status : Published
Global scleroderma diagnostics and therapeutics market expected to generate revenue of around USD 3,165.85 million by end of 2024, growing at a CAGR of around 10.21% between 2018 and 2024. Scleroderma is an autoimmune condition that is characterized by hard and thickened skin along with blood vessel problems.